Avenue Therapeutics Inc (NASDAQ:ATXI)
| 0.709 Delayed Data As of Sep 29 |  +0.038 / +5.66%Today’s Change | 0.54 Today|||52-Week Range 16.65 | -38.88% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $5.5M |
Company Description
Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in Bay Harbor Islands, FL.
Contact Information
Avenue Therapeutics, Inc. 1111 Kane Concourse Bay Harbor Islands Florida 33154 |
Employees
Shareholders
| Other institutional | 7.68% |
| Individual stakeholders | 17.08% |
| Mutual fund holders | 1.22% |
Top Executives
| Alexandra MacLean | Chief Executive Officer & Director |
| David Jin | Secretary, Chief Operating & Financial Officer |
| Scott A. Reines | Chief Medical Officer |
| Michael Ryan | VP-Clinical Operations & Program Management |
| Jaclyn Jaffe | Head-Investor Relations |
